MTOR and colorectal carcinoma: The anti-proliferative action of metformin seems to be mediated by the suppression of the mTOR pathway and IGF1R inactivation36, which both play a critical role in cell growth and are often deregulated in patients with various cancers (including CRC), who have high expression levels of these proteins37.